A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L01A ALKYLATING AGENTS
|
L01B ANTIMETABOLITES
|
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
|
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
|
L01X OTHER ANTINEOPLASTIC AGENTS
|
L01XA Platinum compounds
|
L01XB Methylhydrazines
|
L01XC Monoclonal antibodies
|
L01XC01 Edrecolomab
|
L01XC02 Rituximab
|
L01XC03 Trastuzumab
|
L01XC05 Gemtuzumab ozogamicin
|
L01XC06 Cetuximab
|
L01XC07 Bevacizumab
|
L01XC08 Panitumumab
|
L01XC09 Catumaxomab
|
L01XC10 Ofatumumab
|
L01XC11 Ipilimumab
|
L01XC12 Brentuximab vedotin
|
L01XC13 Pertuzumab
|
L01XC14 Trastuzumab emtansine
|
L01XC15 Obinutuzumab
|
L01XC16 Dinutuximab beta
|
L01XC17 Nivolumab
|
L01XC18 Pembrolizumab
|
L01XC19 Blinatumomab
|
D09325 Blinatumomab (USAN/INN) <JP/US>
|
L01XC21 Ramucirumab
|
L01XC22 Necitumumab
|
L01XC23 Elotuzumab
|
L01XC24 Daratumumab
|
L01XC25 Mogamulizumab
|
L01XC26 Inotuzumab ozogamicin
|
L01XC27 Olaratumab
|
L01XC28 Durvalumab
|
L01XC29 Bermekimab
|
L01XC31 Avelumab
|
L01XC32 Atezolizumab
|
L01XC33 Cemiplimab
|
L01XD Sensitizers used in photodynamic/radiation therapy
|
L01XE Protein kinase inhibitors
|
L01XX Other antineoplastic agents
|
L01XY Combinations of antineoplastic agents
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|